NASDAQ:GPCR Structure Therapeutics (GPCR) Stock Price, News & Analysis $27.03 -0.64 (-2.31%) As of 10:18 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Structure Therapeutics Stock (NASDAQ:GPCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Structure Therapeutics alerts:Sign Up Key Stats Today's Range$27.12▼$28.1350-Day Range$27.67▼$54.7052-Week Range$25.59▼$94.90Volume54,024 shsAverage Volume942,753 shsMarket Capitalization$1.88 billionP/E RatioN/ADividend YieldN/APrice Target$110.91Consensus RatingModerate Buy Company Overview Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs. Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes. Unlike injectable GLP-1 therapies, the candidate is designed as an oral treatment. Structure Therapeutics is also advancing additional discovery and development programs targeting metabolic, cardiovascular and pulmonary diseases. Structure Therapeutics operates internationally, with activities and personnel in the United States and China. The company was formerly known as Shouyao Holdings and became a publicly traded company on the Nasdaq under the symbol GPCR in 2023. Its scientific and executive leadership includes experienced drug-discovery and biotechnology professionals, supported by a team focused on translating structural biology into potential medicines.AI Generated. May Contain Errors. Read More Structure Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreGPCR MarketRank™: Structure Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 467th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingStructure Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 2 strong buy ratings, 12 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialStructure Therapeutics has a consensus price target of $110.91, representing about 310.3% upside from its current price of $27.03.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Structure Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Structure Therapeutics are expected to decrease in the coming year, from ($1.87) to ($2.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Structure Therapeutics is -27.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Structure Therapeutics is -27.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStructure Therapeutics has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Structure Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.04% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 5.23.Change versus previous monthShort interest in Structure Therapeutics has recently increased by 12.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.71 News SentimentStructure Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Structure Therapeutics this week, compared to 4 articles on an average week.Search Interest9 people have searched for GPCR on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows2 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.50% of the stock of Structure Therapeutics is held by insiders.Percentage Held by Institutions91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Structure Therapeutics' insider trading history. Receive GPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GPCR Stock News HeadlinesStructure Therapeutics (NASDAQ:GPCR) Stock Rating Cut to Strong Sell at Wall Street ZenOctober 3 at 1:25 AM | americanbankingnews.comStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Average Target Price of $110.91 According to BrokeragesSeptember 26, 2026 | americanbankingnews.comDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.October 5 at 1:00 AM | Priority Gold (Ad)GPCR Share News TodaySeptember 24, 2026 | uk.investing.comStructure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In FocusSeptember 22, 2026 | finance.yahoo.comStructure Therapeutics Inc ADR (GPCR)September 19, 2026 | za.investing.comStructure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comStructure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?September 10, 2026 | insidermonkey.comSee More Headlines GPCR Stock Analysis - Frequently Asked Questions How have GPCR shares performed this year? Structure Therapeutics' stock was trading at $69.55 on January 1st, 2026. Since then, GPCR stock has decreased by 61.1% and is now trading at $27.03. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.10. When did Structure Therapeutics IPO? Structure Therapeutics (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Structure Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Alamos Gold (AGI), Plug Power (PLUG), KALA BIO (KALA), Ovid Therapeutics (OVID), Comtech Telecommunications (CMTL), Fortress Biotech (FBIO) and Alto Ingredients (ALTO). Company Calendar Last Earnings8/06/2026Today10/05/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GPCR's financial health is in the Red zone, according to TradeSmith. GPCR has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GPCR CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees281Year FoundedN/APrice Target and Rating Average Price Target for Structure Therapeutics$110.91 High Price Target$145.00 Low Price Target$70.00 Potential Upside/Downside+300.8%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$141.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-25.56% Return on Assets-24.31% Debt Debt-to-Equity RatioN/A Current Ratio20.75 Quick Ratio20.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$24.99 per share Price / Book1.11Miscellaneous Outstanding Shares69,620,000Free Float65,792,000Market Cap$1.93 billion OptionableOptionable Beta-1.30 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:GPCR) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
